Tobramycin oral - Enteris BioPharma

Drug Profile

Tobramycin oral - Enteris BioPharma

Alternative Names: Tobramycin sulfate oral - Enteris BioPharma; Tobrate™

Latest Information Update: 15 Jul 2016

Price : $50

At a glance

  • Originator Enteris BioPharma
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Urinary tract infections

Most Recent Events

  • 13 Jul 2016 Phase-I clinical trials in Urinary tract infections (In volunteers) in USA (PO)
  • 05 Jul 2016 Chemical structure information added
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top